I appreciate all the stimulating dialogue in original post and responses. There remains an evidence basis for prazosin’s use in congruence with Yacharter’s experience—as in a review from The Journal of Neuropsychiatry and Clinical Neurosciences by Writer, Meyer, & Schillerstrom (2014)—though the article we read for the journal club (Raskind, Peskind, & Chow, 2018) certainly renders the evidence basis and our clinical decision making more nuanced and complex.
In context of such nuance and complexity, I am even more grateful for the interprofessional approach encouraged by reaching out to our pharmacist colleagues, as I can imagine the benefit of consulting them on such an issue. In addition to interprofessional consultation, the strong replies in this forum also show the benefit of intraprofessional consultation as well, as the future of care really does point more towards the benefit of working as professionals together.
Works Cited:
Raskind, M. A., Peskind, E.R., Chow. B. (2018). Trial of prazosin for post-traumatic stress disorder in military veterans. New England Journal of Medicine, 378, 507-517.
Writer, B. W., Meyer, E. G., & Schillerstrom, J. E. (2014). Prazosin for Military Combat-Related PTSD Nightmares: A Critical Review. The Journal of Neuropsychiatry and Clinical Neurosciences, 26(1), 24-33. doi:10.1176/appi.neuropsych.13010006